Eicosapentaenoic acid (EPA) from highly concentrated n-3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability

References 

1. Bang HO, Dyerberg J, Nielsen AB. Plasma lipid and lipoprotein pattern in Greenlandic West-coast Eskimos. Lancet. 1971;1(1):1143–1145
   • MEDLINE
2. Dyerberg J, Bang HO, Hjorne N. Fatty acid composition of the plasma lipids in Greenland Eskimos. Am J Clin Nutr. 1975;28:958–966
   • MEDLINE
3. GISSI-HF Investigators . Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomized, double blind, placebo-controlled trial. Lancet. 2008;372:1223–1230
   • Abstract
   • Full Text
   • Full-Text PDF (156 KB)
   • CrossRef
4. Roth EM, Harris WS. Fish oil for primary and secondary prevention of coronary heart disease. Curr Atheroscler Rep. 2010;12:66–72
   • CrossRef
5. Mozzafarian D, Fish . Mercury selenium and cardiovascular risk: current evidence and unanswered questions. Int J Environ Res Public Health. 2009;6:1894–1916
6. Thies F, Garry JMC, Yaqoob P, et al. Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomized controlled trial. Lancet. 2003;361:477–485
   • Abstract
   • Full Text
   • Full-Text PDF (123 KB)
   • CrossRef
7. Geleijnse JM, Giltay EJ, Schouten EG, et al. Effect of low doses of n-3 fatty acids on cardiovascular diseases in 4,837 post-myocardial infarction patients: design and baseline of the Alpha Omega Trial. Am Heart J. 2010;159:539–546
   • Abstract
   • Full Text
   • Full-Text PDF (334 KB)
   • CrossRef
8. The ORIGIN Trial Investigators . Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN trial (Outcome Reduction with an Initial Clargine Intervention). Am Heart J. 2008;155:26–32